UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

EASL recommendations on treatment of hepatitis C: Final update of the series

Journal of hepatology, 2020-11, Vol.73 (5), p.1170-1218

2020

Volltextzugriff (PDF)

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

Clinical pharmacology and therapeutics, 2022-12, Vol.112 (6), p.1191-1200

2022

Volltextzugriff (PDF)

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions

Annals of internal medicine, 2022-05, Vol.175 (5), p.744-746

2022

Volltextzugriff (PDF)

EASL Recommendations on Treatment of Hepatitis C 2018

Journal of hepatology, 2018-08, Vol.69 (2), p.461-511

2018

Volltextzugriff (PDF)

Ritonavir and COVID-19: pragmatic guidance is important

The Lancet (British edition), 2022-04, Vol.399 (10334), p.1464-1465

2022

Volltextzugriff (PDF)

FRI-423 Early treatment of patients with indeterminate HBV viraemia does not improve retention in care and risks overtreating patients who may spontaneously clear HBsAg

Journal of hepatology, 2024-06, Vol.80, p.S783-S784

2024

Volltextzugriff (PDF)

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions

British journal of clinical pharmacology, 2021-01, Vol.87 (1), p.212-213

2021

Volltextzugriff (PDF)

P39 Pharmacy preparations for the birth of twins to an ebola survivor

Archives of disease in childhood, 2020-09, Vol.105 (9), p.e27.1-e27

2020

Volltextzugriff (PDF)

Drug interactions: a review of the unseen danger of experimental COVID-19 therapies

Journal of antimicrobial chemotherapy, 2020-12, Vol.75 (12), p.3417-3424

2020

Volltextzugriff (PDF)

Coadministration of hepatitis C direct-acting antivirals and enzyme-inducing antiepileptic drugs: real-world experience from a multi-centre case series

Journal of hepatology, 2023-06, Vol.78, p.S1202

2023

Volltextzugriff (PDF)

THU-210 - Coadministration of hepatitis C direct-acting antivirals and enzyme-inducing antiepileptic drugs: real-world experience from a multi-centre case series

Journal of hepatology, 2023-06, Vol.78, p.S1202-S1202

2023

Volltextzugriff (PDF)

Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool

Journal of hepatology, 2022-07, Vol.77, p.S580-S581

2022

Volltextzugriff (PDF)

Drug–Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort

Clinical infectious diseases, 2016-03, Vol.62 (5), p.561-567

2016

Volltextzugriff (PDF)

SAT080 - PPIs can be discontinued in over 60% of patients with cirrhosis: long term impact of screening for hepatitis C drug interactions

Journal of hepatology, 2020-08, Vol.73, p.S689-S689

2020

Volltextzugriff (PDF)

THU446 - Reasons for direct acting antiviral failure in patients referred for multi-disciplinary team discussion and virological outcomes of retreatment

Journal of hepatology, 2020-08, Vol.73, p.S361-S361

2020

Volltextzugriff (PDF)

PPIs can be discontinued in over 60% of patients with cirrhosis: long term impact of screening for hepatitis C drug interactions

Journal of hepatology, 2020-08, Vol.73, p.S689

2020

Volltextzugriff (PDF)

Reasons for direct acting antiviral failure in patients referred for multi-disciplinary team discussion and virological outcomes of retreatment

Journal of hepatology, 2020-08, Vol.73, p.S361

2020

Volltextzugriff (PDF)

Fluvoxamine for the treatment of COVID-19

The Lancet global health, 2022-03, Vol.10 (3), p.e331-e331

2022

Volltextzugriff (PDF)

Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature

Journal of acquired immune deficiency syndromes (1999), 2023-02, Vol.92 (2), p.97-105

2023

Volltextzugriff (PDF)

THU-156-Real world outcomes for Genotype 3 patients treated with glecaprevir/pibrentasvir: Real world outcomes from an unselected cohort

Journal of hepatology, 2019-04, Vol.70 (1), p.e230-e231

2019

Volltextzugriff (PDF)

FRI-251-Impact of hepatitis C treatment on patterns of drug use and subsequent treatment outcomes: High SVR rates despite increasing intravenous drug use in the post treatment period

Journal of hepatology, 2019-04, Vol.70 (1), p.e504-e505

2019

Volltextzugriff (PDF)

THU-121-Real world outcomes from NS5a treatment failures undergoing therapy with sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/ glecaprevir/pibrentasvir

Journal of hepatology, 2019-04, Vol.70 (1), p.e212-e212

2019

Volltextzugriff (PDF)

The Collaborative Care Model: Realizing healthcare values and increasing responsiveness in the pharmacy workforce

Research in social and administrative pharmacy, 2023-01, Vol.19 (1), p.110-122

2023

Volltextzugriff (PDF)

Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment

Drugs in R&D, 2021-03, Vol.21 (1), p.9-27

2021

Volltextzugriff (PDF)

The quetiapine question: management strategies for drug-drug interactions with antipsychotics and direct acting antivirals; a multicentre review

Journal of hepatology, 2020-08, Vol.73, p.S349

2020

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(52)

Publikationsform

Sprache

Englisch
(59)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

EASL recommendations on treatment of hepatitis C: Final update of the series

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions

EASL Recommendations on Treatment of Hepatitis C 2018

Ritonavir and COVID-19: pragmatic guidance is important

FRI-423 Early treatment of patients with indeterminate HBV viraemia does not improve retention in care and risks overtreating patients who may spontaneously clear HBsAg

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions

P39 Pharmacy preparations for the birth of twins to an ebola survivor

Drug interactions: a review of the unseen danger of experimental COVID-19 therapies

Coadministration of hepatitis C direct-acting antivirals and enzyme-inducing antiepileptic drugs: real-world experience from a multi-centre case series

THU-210 - Coadministration of hepatitis C direct-acting antivirals and enzyme-inducing antiepileptic drugs: real-world experience from a multi-centre case series

Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool

Drug–Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort

SAT080 - PPIs can be discontinued in over 60% of patients with cirrhosis: long term impact of screening for hepatitis C drug interactions

THU446 - Reasons for direct acting antiviral failure in patients referred for multi-disciplinary team discussion and virological outcomes of retreatment

PPIs can be discontinued in over 60% of patients with cirrhosis: long term impact of screening for hepatitis C drug interactions

Reasons for direct acting antiviral failure in patients referred for multi-disciplinary team discussion and virological outcomes of retreatment

Fluvoxamine for the treatment of COVID-19

Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature

THU-156-Real world outcomes for Genotype 3 patients treated with glecaprevir/pibrentasvir: Real world outcomes from an unselected cohort

FRI-251-Impact of hepatitis C treatment on patterns of drug use and subsequent treatment outcomes: High SVR rates despite increasing intravenous drug use in the post treatment period

THU-121-Real world outcomes from NS5a treatment failures undergoing therapy with sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/ glecaprevir/pibrentasvir

The Collaborative Care Model: Realizing healthcare values and increasing responsiveness in the pharmacy workforce

Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment

The quetiapine question: management strategies for drug-drug interactions with antipsychotics and direct acting antivirals; a multicentre review

Suchergebnisse filtern